Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




Rapid POC Tuberculosis Test Provides Results Within 15 Minutes

By HospiMedica International staff writers
Posted on 09 Dec 2025

Tuberculosis remains one of the world’s deadliest infectious diseases, and reducing new cases depends on identifying individuals with latent infection before it progresses. More...

Current diagnostic tools often require advanced laboratory infrastructure, trained personnel, and long processing times, making them difficult to implement in rural or low-resource regions. In a new study, researchers evaluated a rapid test that delivers same-day results without specialized equipment, aiming to expand access to preventive treatment.

Researchers at Karolinska Institutet (Solna, Stockholm, Sweden), working with collaborators in Vietnam, assessed TB-Feron, a point-of-care test that detects latent tuberculosis infection within 15 minutes. They compared it to the standard laboratory test, QuantiFERON-TB Gold Plus, which requires multiple processing steps and one to two days for results. The study included 345 adults divided into three groups based on confirmed TB status, household exposure, or no known exposure. All participants were tested using both methods for direct comparison.

The findings, published in Clinical Infectious Diseases, showed that TB-Feron had a high sensitivity of 88%, identifying most individuals expected to test positive. QuantiFERON-TB Gold Plus showed a slightly higher sensitivity of 92%. Specificity for TB-Feron reached 70%, compared with 96% for the standard test, indicating a moderate ability to rule out infection in healthy individuals. Among household contacts, the two tests showed strong agreement, with 92% concordance in positive samples.

Researchers also assessed reproducibility to ensure the test’s reliability in real-world settings. Their findings from two laboratory groups showed no systematic differences, supporting consistent test performance across operators. The team noted that TB-Feron’s rapid, user-friendly format made it particularly practical for primary care and community-based screening where laboratory services are limited. They anticipate that this approach could improve early detection and broaden access to preventive therapy.

“This test can help more people with latent tuberculosis to be detected and receive preventive treatment, especially in rural areas in countries with limited resources,” said Lina Davies Forsman, last author of the study.

Related Links:
Karolinska Institutet


Gold Member
STI Test
Vivalytic Sexually Transmitted Infection (STI) Array
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Floor‑Mounted Digital X‑Ray System
MasteRad MX30+
Emergency Ventilator
Shangrila935
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: Medtronic’s intent to acquire CathWorks follows a 2022 strategic partnership with a co-promotion agreement for the FFRangio System (Photo courtesy of CathWorks)

Medtronic to Acquire Coronary Artery Medtech Company CathWorks

Medtronic plc (Galway, Ireland) has announced that it will exercise its option to acquire CathWorks (Kfar Saba, Israel), a privately held medical device company, which aims to transform how coronary artery... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.